# Anondita Medicare share price today (Anondita Medicare Ltd, NSE: ANONDITA) > Anondita Medicare share price today: ₹1,059.30 at the NSE close on 18 November 2026, up 70.4% in a year. Anondita Medicare (NSE: ANONDITA) is worth ₹2,017 crore, trades at a P/E of 60.3 and has closed between ₹606.43 and ₹1,233.15 over the past 52 weeks. > Anondita Medicare Ltd's multiple is near its low because earnings grew even faster than a big multi-year rise in the share price. The multiple is low because of growth, not neglect. Results are still improving, and its P/E is higher than only 35% of its own 1-year history. ANONDITA · Contraceptives/Protectives · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/anondita-medicare-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹1,059.30 (+70.4% in a year) - P/E: 60.3× (lower than 65% of the last 1 year) - Revenue (Mar 2026): ₹83.0 Cr (+80.4% on a year ago) - Profit (Mar 2026): ₹21.0 Cr (+110.0% on a year ago) - Operating margin: 37.3% (+2.5 points on a year ago) - ROCE: 44%, FY26 - ROIC: 23.8%, against a 12.0% cost of capital: +11.8 points - Profit that came in as cash: 8%, last 2 years The main question: profits are rising, but only 8% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Anondita Medicare share price today? Anondita Medicare Ltd's share price was ₹1,059.30 at the close on 18 November 2026. It has been rising for 58 weeks. That is 11.1% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹606 and ₹1,233, and at that close it sat 72% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running. Over the last 1 year the share price moved +211% while the NIFTY 500 moved +4%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 13 November 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What are Anondita Medicare's latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), Anondita Medicare reported revenue of ₹83.0 crore, up 80.4% from ₹46.0 crore a year earlier, and a profit of ₹21.0 crore, up 110.0% from ₹10.0 crore. ### Anondita Medicare results: January to March 2026 against a year earlier | Measure | January to March 2026 | January to March 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹83.0 crore | ₹46.0 crore | +80.4% | | Profit | ₹21.0 crore | ₹10.0 crore | +110.0% | | Earnings per share | ₹10.41 | ₹7.60 | +37.0% | | Operating margin | 37.3% | 34.8% | +2.5 points | The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them. The newest call in our records is from 16 November 2026, about July to September 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.) ## What is the Anondita Medicare share price history? Anondita Medicare closed at ₹1,059.30 on 18 November 2026, up 70.4% from ₹621.80 a year earlier (21 November 2025). Its highest weekly close since September 2025 was ₹1,233.15 on 24 June 2026. ### Anondita Medicare share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹1,056.60 | +0.3% | | 1 month ago · 19 Oct 2026 | ₹1,007.45 | +5.1% | | 6 months ago · 15 May 2026 | ₹929.65 | +13.9% | | 1 year ago · 21 Nov 2025 | ₹621.80 | +70.4% | | Earliest and lowest weekly close in our records · 5 Sep 2025 | ₹340.80 | +210.8% | | Highest weekly close since September 2025, also the 52-week high · 24 Jun 2026 | ₹1,233.15 | −14.1% | | 52-week low (weekly close) · 25 Nov 2025 | ₹606.43 | +74.7% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (68 weekly closes from 5 September 2025 to 18 November 2026.) ## What is the latest news on Anondita Medicare? 18 Nov 2026: Anondita Medicare closed at ₹1,059.30, up 0.3% on the week and up 5.1% on the month. 16 Nov 2026: Anondita Medicare held its results call for July to September 2026. Management guided: FY27 revenue ₹240 crore to ₹250 crore. ### Earlier - Results for January to March 2026: Revenue up 80.4% and profit up 110.0% on a year earlier. ## What dividend does Anondita Medicare pay? Anondita Medicare has paid no dividend on the NSE since its first NSE close in our records (5 September 2025), the start of the period we checked. No. Anondita Medicare Ltd paid out 0% of its profit as dividends in each of its last 2 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Anondita Medicare management say on the latest results call? On the call for July to September 2026, held on 16 November 2026, Anondita Medicare's management guided: FY27 revenue ₹240 crore to ₹250 crore. > “We would proudly say that we are the only company in the world that manufactures male latex, male non-latex, female latex, and female non-latex condoms.” > Anupam Ghosh, on the call for July to September 2026 ### What management guided - FY29 revenue ₹1,000 crore. - Male annual capacity 1.1 billion pieces by month-end with 4 lines commercial within 2 weeks. - Female latex 60M capacity across 2 lines ready by December, trials complete finishing underway. - Female non-latex 2 lines about 120M each to commercial production within FY27, trials starting by December. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/58631-16-Nov-2026.pdf). (From the call for July to September 2026, 16 November 2026.) ## What to watch in Anondita Medicare's next results? When Anondita Medicare reports April to June 2026, these are the 2 checks that show whether the story is still on course. First: H2 conversion of in-hand domestic, South Africa and own-brand orders with monthly shipments already started. Management raised each of these on the latest results call. - H2 conversion of in-hand domestic, South Africa and own-brand orders with monthly shipments already started. - Male scale-up commissioning and female latex and non-latex trial-to-commercial milestones against guided timelines. ## Which stock lists is Anondita Medicare on? Anondita Medicare is not on any of our India lists this week. ## Is Anondita Medicare profitable? Anondita Medicare Ltd earned ₹21.0 Cr of net profit in the Mar 2026 quarter, +110.0% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹34.0 Cr. The Mar 2026 quarter's profit is 25.3% of that quarter's revenue. For the full year, FY26 profit was ₹34.0 Cr (+112.5% on the year before). ## How much revenue does Anondita Medicare make, and is it growing? Anondita Medicare Ltd reported ₹83.0 Cr of revenue in the Mar 2026 quarter, +80.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. The last full year, FY26, came in at ₹137 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly. FY26 revenue was ₹137 Cr, +77.9% on the year before. ## How much of every ₹100 of sales does Anondita Medicare keep? Anondita Medicare Ltd's operating margin was 37.3% in the Mar 2026 quarter, 2.5 percentage points higher than the same quarter a year ago. Across 2 years it has been between 33.8% and 37.2%. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## Is Anondita Medicare's profit turning into cash? Over the last 2 years, 8% of Anondita Medicare Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹11.0 Cr of operating cash against ₹34.0 Cr of profit. After ₹63.0 Cr of spending on assets, free cash was −₹52.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 8% of profit came in as cash: the cash cycle stayed about the same between FY25 and FY26, so the cash follows profit, not the cycle. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: the bigger use of cash is spending on new assets, at 37.0× depreciation over three years. The next section checks what that spending is building. ## Where does Anondita Medicare's cash go? Anondita Medicare Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 214 days in FY26, down from 218 days in FY25. It spent ₹74.0 Cr on assets over the last 3 years. Customers take 138 days to pay, and stock sits for 125 days on average. At FY26 sales of ₹137 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹80.0 Cr is tied up in the business at any time. FY26: customers took 138 days to pay and stock sat for 125 days, about 4.1 months of sales sitting as stock, for a full cycle of 214 days, shorter than FY25's 218. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 125 days. Customers pay about 138 days after that. Suppliers are paid at 48 days. Together that makes the 214-day cycle. Spending on assets: ₹74.0 Cr over the last 3 years, against ₹2.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹42.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Anondita Medicare's P/E ratio, and how does it compare with its own history? Anondita Medicare Ltd's P/E is 60.3×, near the low end of its own history: it has been lower only 35% of the time. Its usual P/E (the middle reading) is 64.0×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +55.1% while the price moved +70.4%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Anondita Medicare business getting better or worse? Anondita Medicare Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Anondita Medicare earn on its capital? Anondita Medicare Ltd earned a ROCE of 44% in FY26. Its return on capital used (ROIC) is 11.8 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 24.8% net margin and 0.74× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 24.8% net margin × 0.74× asset turnover × 1.43× leverage (assets divided by equity) ≈ 26.2% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 23.8% − 12.0% = +11.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 23.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 33.3%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Anondita Medicare have too much debt? Anondita Medicare Ltd had ₹34.0 Cr of borrowings against ₹129 Cr of equity in FY26, so its debt is 0.26× its equity. Its operating profit is 13 times its interest bill. Over 2 years borrowings went from ₹0.0 Cr to ₹34.0 Cr. Over the last 3 of those years it spent ₹74.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the Anondita Medicare shareholding pattern? No group of Anondita Medicare Ltd's owners changed its stake by a full percentage point over the last 3 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is Anondita Medicare from balance-sheet trouble? For Anondita Medicare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Anondita Medicare rank in its industry? 59.4 out of 100, rank 2 of 2 in Contraceptives/Protectives, with 28% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Anondita Medicare Ltd scores 59.4 out of 100 against the 2 companies it is compared with in Contraceptives/Protectives, ranking 2. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 17.6 + 19.3 + 10 + 12.5 = 59.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Anondita Medicare compared with? Anondita Medicare ranks 2 of 2 Contraceptives/Protectives companies on the 4-Factor Sector Score, with 59.4 out of 100. 1. [Cupid Ltd](https://www.sectoralpha.in/stocks/cupid-ltd) CUPID · leader · Most evidence points up · 80% evidence 79.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 100% · Profit 100% · Operating margin change -5 points · 100% evidence Capital efficiency 21.0/25 · ROCE 33.9% (year to Mar 2026) · Operating margin 29.3% · 100% evidence Valuation 10.0/20 · P/E 288.3× · PEG n/a · 0% evidence Relative strength 20.0/20 · Strength vs its industry (price vs its 52-week average, weekly) 39.4% · Strength vs NIFTY 500 (same reading) 112.7% · 1 year 439.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 28 + 21 + 10 + 20 = 79 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. Anondita Medicare Ltd this page ANONDITA · quiet · Too little evidence to rank firmly · 28% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.6/35 · Revenue n/a · Profit n/a · Operating margin change 3 points · 15% evidence Capital efficiency 19.3/25 · ROCE 43.8% (year to Mar 2026) · Operating margin 37.4% · 71% evidence Valuation 10.0/20 · P/E 60.3× · PEG n/a · 0% evidence Relative strength 12.5/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 8.2% · 1 year 70.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 17.6 + 19.3 + 10 + 12.5 = 59.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Contraceptives/Protectives](https://www.sectoralpha.in/sectors/contraceptives-protectives), all 2 compared on one page. ## Which companies are close to Anondita Medicare in size? Anondita Medicare is the 2nd largest of 2 Contraceptives/Protectives companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Cupid. It is the smallest. ### Contraceptives/Protectives companies close in size 1. [Cupid Ltd](https://www.sectoralpha.in/stocks/cupid-ltd) ₹48,838 crore 2. Anondita Medicare Ltd ₹2,018 crore ### Companies close in size in other industries 1. [Max India Ltd(Merged)](https://www.sectoralpha.in/stocks/max-india-ltd-merged) ₹2,029 crore · Hospitals & Diagnostics 2. [Geojit Financial Services Ltd](https://www.sectoralpha.in/stocks/geojit-financial-services-ltd) ₹2,025 crore · Finance - Capital Markets - Brokers 3. Anondita Medicare Ltd ₹2,018 crore 4. [Paramount Communications Ltd](https://www.sectoralpha.in/stocks/paramount-communications-ltd) ₹2,012 crore · Cables - Telecom 5. [Orissa Minerals Development Company Ltd](https://www.sectoralpha.in/stocks/orissa-minerals-development-company-ltd) ₹2,008 crore · Mining/Minerals ## What else do people ask about Anondita Medicare? ### What is Anondita Medicare's share price today? Anondita Medicare Ltd's share price is ₹1,059.30, +70.4% over the past year. The whole company is worth ₹2,017 Cr on the market. In the last 52 weeks it traded between ₹606 to ₹1,233; today it is 72% of the way up from the low, 11.1% above its 200-day average (as of 18 November 2026). ### What were Anondita Medicare's latest quarterly results? Anondita Medicare Ltd reported revenue of ₹83.0 Cr and net profit of ₹21.0 Cr for the Mar 2026 quarter. Revenue rose 80.4% and profit rose 110.0% compared with a year earlier. Earnings per share were ₹10.41. The operating margin was 37.3%, 2.5 percentage points higher than a year earlier (as of 18 November 2026). ### What is Anondita Medicare's market cap? Anondita Medicare Ltd's market capitalisation is ₹2,017 Cr at a share price of ₹1,059.30. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Anondita Medicare performing? Anondita Medicare Ltd's share price has been rising for 58 weeks. In its latest quarter, revenue rose 80.4% and profit rose 110.0% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 18 November 2026). ### Will Anondita Medicare's share price go up? This page does not forecast Anondita Medicare Ltd's share price. What it shows instead: the share price is ₹1,059.30, and it has been rising for 58 weeks. Its P/E of 60.3× is higher than 35% of its own last 1 years (as of 18 November 2026). ### Who owns Anondita Medicare? Promoters own 59.3% of Anondita Medicare Ltd, foreign institutions 2.6%, domestic institutions 6.1% and the public 32.1% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 18 November 2026). ### Where is Anondita Medicare in its business cycle? Anondita Medicare Ltd's FY26 operating margin was 37.2%, against a 2-year range of 33.8% to 37.2%. The latest quarter was 37.3%, above the top of its own yearly range in the latest quarter, so margins are at a high and the story depends on them staying there. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Anondita Medicare story? The main question: profits are rising, but only 8% of the last 2 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Anondita Medicare a stock worth studying right now? What the numbers show: Anondita Medicare Ltd's multiple is near its low because earnings grew even faster than a big multi-year rise in the share price. The multiple is low because of growth, not neglect. Results are still improving, and its P/E is higher than only 35% of its own 1-year history. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Anondita Medicare share price forecast for 2026? What management itself guided: FY27 revenue ₹240 crore to ₹250 crore. This is research, not advice. We’re not SEBI-registered.